ARIZ Precision Medicine

Executive Summary

ARIZ Precision Medicine is a preclinical-stage biopharmaceutical company developing first-in-class, curative cancer therapies. The company combines a proprietary methodology to identify and target the root genetic drivers of cancer with a nanotechnology-based targeted drug delivery system (T-DDS) that delivers siRNA payloads specifically to cancer cells. Founded in 2018 and headquartered in Phoenix, AZ, ARIZ aims to stop cancer growth and metastasis by addressing the initial genetic errors causing the disease. Its platform offers a novel approach to precise genetic silencing, potentially overcoming long-standing delivery challenges in oncology. As ARIZ progresses toward the clinic, near-term priorities include completing IND-enabling studies and securing additional funding. Success in preclinical efficacy and safety could support an IND filing within the next 12–18 months. The company's innovative dual-platform strategy positions it to address high-unmet-need solid tumors, though clinical validation remains years away. Key upcoming catalysts include financing events, potential partnerships to expand platform applications, and regulatory milestones that will shape its trajectory.

Upcoming Catalysts (preview)

• Q1 2027Completion of IND-enabling studies and IND filing for lead candidate50% success
• Q3 2026Series A financing round70% success
• Q4 2026Strategic partnership for T-DDS platform or co-development agreement40% success